News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

PHARMAC invests $103 million in NZers’ health

Media release

PHARMAC invests $103 million in NZers’ health

An extra $103 million is being invested in New Zealanders’ health over the next five years as a result of recent pharmaceutical funding decisions.

PHARMAC Chief Executive Wayne McNee says the current financial year, which began on 1 July, has seen a continued acceleration in PHARMAC’s programme of new investments.

Funding decisions made since 1 July have included adding new treatments for rheumatoid arthritis, heart disease, pain, multiple sclerosis and Parkinson’s Disease. Access has also been widened to treatments for transplant rejection, diabetes, osteoporosis and asthma.

Further new funding decisions are in the pipeline including treatments for some forms of cancer, and for diabetes.

The largest single funding decision made this year has involved the rheumatoid arthritis drug adalimumab (Humira). The drug is one of a relatively new class of treatments called TNF alpha inhibitors and helps to halt the progression of arthritis.

“At $35 million over five years the listing of adalimumab is by far the largest investment we have made so far this year,” Wayne McNee says.

“We’re delighted to be able to put these decisions in place, and are confident that they will both improve people’s health and, in some cases, produce downstream savings in other areas of health spending.”

“For example, an increase in the number of people taking alendronate for osteoporosis could reduce the number of hip replacements in the future. And low-dose aspirin has good evidence to show that it is an effective and low-cost way of avoiding heart attacks and strokes.”

Wayne McNee says PHARMAC continues to carefully assess the treatments it is funding, and adds: “We remain committed to giving New Zealanders better access to new medicines, and making sure that money is spent on medicines that add value to current treatment options.”

The pharmaceutical budget for 2006 is $582 million, an increase of 3.2% over 2005, and PHARMAC has an agreed three-year funding pathway for pharmaceuticals which includes ongoing increases in the budget.

“The full impact of the funding decisions we have made this year will be felt in the future,” he adds. “We are pleased that there is a commitment to ongoing increases in expenditure, as this will enable us to continue to fund the medicines that are already subsidised, and to add more medicines that will improve the health of New Zealanders.”

Investments to date in 2005-06.

Drug Investment type Treats 5-year investment (NPV)
Adalimumab
New medicine Rheumatoid arthritis $35 million
Alendronate Wider access Osteoporosis $8.9 million
Gabapentin Wider access Pain relief $18 million
Low-dose aspirin New medicine Heart disease $17 million
Mycophenolate Wider access Transplant rejection $8 million
Oxycodone New medicine Pain relief $5 million
Pioglitazone Wider access Diabetes $0.7 million
Ropinirole and entacapone New medicines Parkinsons Disease $2.4 million
Salmeterol Wider access Asthma $8 million
Total $103 million


ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Reuben Moss' Property is Theft! & Kaitani at The Physics Room

Property is Theft! continues Moss’ interest in the contemporary urban environment as a space controlled by pulsing and unequal flows of capital and labour. Kaitani features work by the University of Canterbury Fijian Students Association and Kulimoe’anga Stone Maka. More>>


Handcrafted Form: Rare Treasures From Japan

This unique exhibition at Expressions Whirinaki represents 90 everyday objects made by contemporary Japanese artisans who employ various traditional craft techniques made in regional workshops. The works used in daily life are crafted from raw materials with techniques appropriate to bringing out the best of its medium, balancing ease of use with aesthetic appeal. More>>

Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland